Manila Times Business
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. Exton, PA, June 12, 2026 (GLOBE NEWSWIRE) -- Despite widespread recognition that long-term steroid exposure should be minimized in patients with warm autoimmune hemolytic anemia (w-AIHA), treatment patterns remain heavily reliant on corticosteroids and rituximab, high
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
Just now
What Is XM Partner Code Y8MH4 and Why Is It Growing?
1h ago
Eight Saints Launches Firm Intentions, a Clean Anti-Aging Neck Cream, Targeting Skincare's Most Overlooked Area
1h ago
Limitless Sky Launches empty-legs-flights.com - The World’s Most Comprehensive Real-Time Empty Leg Private Jet Platform
1h ago